Recent Finacing
Recent Raise
Sanaria develops radiation‑attenuated whole‑organism PfSPZ malaria vaccines, a PfSPZ‑CVac chemoprophylaxis candidate, human monoclonal antibodies for short‑term malaria protection, and an oral SARS‑CoV‑2 vaccine.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Sanaria Inc..
